Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT04711850
Other study ID # 20-HMedIdes-18
Secondary ID 2020-004777-49
Status Terminated
Phase
First received
Last updated
Start date January 21, 2021
Est. completion date March 30, 2023

Study information

Verified date April 2023
Source Hansa Biopharma AB
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The aim of this trial is to collect data and provide a better understanding of the long-term outcome of imlifidase treatment on active or chronic active antibody-mediated rejection (AMR) in kidney transplant recipients. This is done by collecting data during an extended follow-up period of 3 years of clinical study trial 16-HMedIdeS-12, in which patients received either imlifidase or plasma exchange (PE) as AMR treatment. Data for parameters such as kidney graft survival, patient survival, kidney function, treatment of rebound of donor specific antibodies (DSA) and anti-drug antibodies (ADAs) are collected.


Description:

AMR is one of the most challenging adverse events following kidney transplantation and a major cause of graft dysfunction and graft loss. AMR is triggered by donor-specific antibodies (DSA).Transplant glomerulopathy is a known consequence of persistent DSA positivity which results in graft failure and return to dialysis with attendant consequences for the patient and financial costs for the health care system. The time from transplantation to onset of clinical symptoms of AMR varies largely between individuals. An early AMR (<30 days post-transplant) is commonly classified as active AMR and most often triggered by an immunological recall response with pre-existing DSA. A late AMR (>30 days post-transplant) is classified as either active or chronic active AMR and is caused by either a recall DSA response or newly developing naïve immune response associated with de novo DSA production. There is no currently approved therapy for AMR and patients are often treated with a combination of therapies i.e., high dose IVIg +/- rituximab, PE with low dose IVIg +/- rituximab, and eculizumab which makes analysis of efficacy of any single agent difficult. Hence, there is a large unmet clinical need for new therapies to treat AMR. Imlifidase is an IgG-degrading enzyme of Streptococcus pyogenes that cleaves all four human subclasses of IgG with high efficacy and specificity. The rapidity of the IgG cleavage by imlifidase is considered a major advantage as compared with PE, which often requires several rounds over several days to achieve a sufficient DSA reduction. Within a few hours after imlifidase dosing, the entire pool of IgG is completely cleaved and thereby a window where IgG levels are kept very low for approximately one week is created. The short-term efficacy and safety of imlifidase in active and chronic active AMR is being investigated in a randomized, open-label, multi-centre trial, using PE as an active control (i.e. the feeder study: 16-HMedIdeS-12). A total of 30 subjects will be included in this study (20 in the imlifidase arm and 10 in the plasma exchange arm). The primary objective is to investigate the efficacy of imlifidase in removing DSA in patients who are experiencing an AMR episode after kidney transplantation. While a rapid removal of DSA by imlifidase might be expected, DSA is likely to rebound unless well-controlled by concomitant immunosuppressive therapy. Therefore, there is also a need to address the long-term outcome of imlifidase as an AMR therapy. This will be studied during an extended follow-up period of 3 years in this study. Data for parameters such as kidney graft survival, patient survival, kidney function, treatment of rebound of donor specific antibodies (DSA) and anti-drug antibodies (ADAs) will be collected.


Recruitment information / eligibility

Status Terminated
Enrollment 18
Est. completion date March 30, 2023
Est. primary completion date March 30, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Signed Informed Consent obtained before any trial-related procedures - Willingness and ability to comply with the protocol - Previous treatment with imlifidase or plasma exchange in the trial 16-HMedIdeS-12 Note: The primary objective of this trial is overall graft survival after treatment with imlifidase or plasma exchange. Therefore, subjects can also be included even if the subject did not fully complete the feeder trial follow up but was dosed with imlifidase or plasma exchange in the trial 16-HMedIdeS-12. Exclusion Criteria: • Inability by the judgement of the investigator to participate in the trial for any other reason

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Imlifidase
Immunoglobulin G degrading enzyme of Streptococcus pyogenes

Locations

Country Name City State
Austria Universitätsklinik für Innere Medizin III, Klinische Abteilung für Nephrologie MUW Vienna
France Hôpital Pellegrin Bordeaux
France CHU Grenoble Alpes - Néphrologie, dialyse et transplantation Grenoble
France Hôpital Necker - Service de Néphrologie - Transplantation Paris
France Hôpital Saint-Louis. Service de Néphrologie et Transplantation Paris
Germany Medizinische Hochschule Hannover Hannover

Sponsors (1)

Lead Sponsor Collaborator
Hansa Biopharma AB

Countries where clinical trial is conducted

Austria,  France,  Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Overall graft survival at Year 3 Graft survival is defined as time from start of AMR treatment in feeder study (16-HMedIdeS-12) to graft loss. Graft loss is defined as permanent return to dialysis for at least 6 weeks, re-transplantation, or nephrectomy. 3 years after start of AMR treatment in feeder study (16-HMedIdeS-12)
Secondary Overall graft survival at Year 1 and Year 2 Graft survival is defined as time from start of AMR treatment in feeder study (16-HMedIdeS-12) to graft loss. Graft loss is defined as permanent return to dialysis for at least 6 weeks, re-transplantation, or nephrectomy. 1 and 2 years after start of AMR treatment in feeder study (16-HMedIdeS-12)
Secondary Patient survival at Year 3 Overall patient survival is defined as time from start of AMR treatment in feeder study (16-HMedIdeS-12) to death for any cause. 3 years after start of AMR treatment in feeder study (16-HMedIdeS-12)
Secondary Kidney function as evaluated by eGFR Estimated glomerular filtration rate (eGFR) was calculated as described by the Modification of Diet in Renal Disease Study (MDRD) equation. eGFR is a measure of kidney function. eGFR for a kidney with normal function is 90 mL/min/1.72m2. Kidney disease is characterised by a decreased eGFR value. 1, 2 and 3 years after start of AMR treatment in feeder study (16-HMedIdeS-12)
Secondary Kidney function as evaluated by S/P-creatinine S/P-creatinine is a measure of kidney function. Kidney disease is characterized by an increased S/P-creatinine level. 1, 2 and 3 years after start of AMR treatment in feeder study (16-HMedIdeS-12)
Secondary Kidney function as evaluated by albumin/creatinine ratio (ACR) in urine ACR in urine is a measure of kidney function. Kidney disease is characterized by an increased ACR in urine. 1, 2 and 3 years after start of AMR treatment in feeder study (16-HMedIdeS-12)
Secondary Presumed or Biopsy proven AMR episodes Information about rejection episodes will be collected, according to Banff 2017 or later classification. For-cause biopsies together with contemporaneous local DSA analyses, kidney function parameters (creatinine, albumin/creatinine ratio in urine) and treatments (e.g. plasma exchange and IVIg) will be collected to assess the rejection episodes. 3 years after start of AMR treatment in feeder study (16-HMedIdeS-12)
Secondary Presumed or Biopsy-proven rejection episodes, (other than AMR episodes) Information about rejection episodes will be collected, according to Banff 2017 or later classification. For-cause biopsies together with contemporaneous local DSA analyses, kidney function parameters (creatinine, albumin/creatinine ratio in urine) and treatments (e.g. plasma exchange and IVIg) will be collected to assess the rejection episodes. 3 years after start of AMR treatment in feeder study (16-HMedIdeS-12)
Secondary DSA levels DSA levels will be measured using single antigen bead human leukocyte antigen (SAB-HLA) assay 1, 2 and 3 years after start of AMR treatment in feeder study (16-HMedIdeS-12)
Secondary ADA levels The immunogenicity of imlifidase will be assessed by measuring ADA levels. 1,2 and 3 years after start of AMR treatment in feeder study (16-HMedIdeS-12)
See also
  Status Clinical Trial Phase
Recruiting NCT04491552 - TruGraf® Long-term Clinical Outcomes Study
Withdrawn NCT04560582 - Immunosuppression Reduction in Failed Allograft Guided by cfDNA
Completed NCT05747274 - SRDK0921_ Analytical Performance Study
Not yet recruiting NCT05482100 - CLinical Utility of the omnigrAf® biomarkeR Panel In The Care of kidneY Transplant Recipients
Recruiting NCT06243289 - Improving KIdney Transplantation With Cellular Therapy Study
Not yet recruiting NCT06025240 - Expanding the Scope of Post-transplant HLA-specific Antibody Detection and Monitoring in Renal Transplant Recipients
Completed NCT04367610 - Effects of A Standardized Treatment Approach on Kidney Transplant Recipients With Antibody-Mediated Rejection
Enrolling by invitation NCT06126380 - Long-Term Safety and Efficacy of Tegoprubart in Kidney Transplant Recipients Phase 2
Terminated NCT05747053 - Personalization of Immunosuppressive Treatment for Organ Transplant Recipients
Active, not recruiting NCT03714113 - Donor-specific Anti-HLA Antibodies Monitoring in Kidney Transplant Recipients N/A
Recruiting NCT04091984 - The PROspera Kidney Transplant ACTIVE Rejection Assessment Registry (ProActive)
Recruiting NCT05335538 - TruGraf and TRAC In Pediatrics Study
Completed NCT03663335 - Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Kidney Transplant Recipients Phase 2
Completed NCT03652402 - Precision Risk Stratification in Kidney Transplant Patients - EU-TRAIN
Recruiting NCT04773392 - Simplified IMmunosuppressive Protocol Utilizing Low Dose EnvarsusXR Phase 4
Completed NCT03873623 - The TOGETHER Project - Kidney
Terminated NCT02974686 - Conversion From MPA to Zortress (Everolimus) for GI Toxicity Post-renal Transplantation Phase 4
Terminated NCT04156204 - Immunosuppressant Medication Dosed Daily After Kidney Transplant Early Phase 1
Completed NCT04601155 - Transition of Renal Patients Using AlloSure Into Community Kidney Care
Completed NCT03874299 - The TOGETHER Project - Kidney RNA-seq Validation